| Viatris (Nasdaq: VTRS) sounds like a drug for men that you may see advertised during a football game or on Antiques Roadshow, but it's a company that does make pharmaceuticals for a variety of medical specialties, including oncology, respiration and women's healthcare, among others. Viatris pays a $0.12 per share quarterly dividend, which comes out to a 5.1% yield. Let's see if it's sustainable. Last year, Viatris' free cash flow was lower than it was in 2021 - but barely. In 2021, free cash flow totaled $2.556 billion. Last year, that figure came in at $2.546 billion, which means cash flow declined by 0.4%. So it's a rounding error, really. However, Safety Net errs on the side of being conservative. If free cash flow falls by as much as $1, Safety Net's spidey senses start tingling and it lowers the stock's dividend safety grade. The company was created by a merger of Mylan and Upjohn. The combined company has been paying a dividend since 2021. It raised it in 2022. But because the dividend-paying history is so short, the Safety Net algorithm doesn't trust the company yet. It's like even if the guy your daughter is dating brings her home by 11 on the first date, it doesn't mean a whole lot. It's going to take a while for this punk to earn your trust. As far as Safety Net is concerned, Viatris is that young punk. The good news is Viatris did bring your daughter home on time and was very polite with a respectable 23% payout ratio (forecast to dip to 21%). That means the company paid out only 23% of its free cash flow in dividends. |
No comments:
Post a Comment
Keep a civil tongue.